OX40‐targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice

Bibliographic Details
Title: OX40‐targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice
Authors: Yee C. Tee, Stephen J. Blake, David J. Lynn
Source: FASEB BioAdvances, Vol 3, Iss 10, Pp 829-840 (2021)
Publisher Information: Wiley, 2021.
Publication Year: 2021
Collection: LCC:Biology (General)
Subject Terms: hepatoxicity, immune agonist antibody, immunotherapy, liver, microbiota, natural killer T cells, Biology (General), QH301-705.5
More Details: Abstract Despite promising preclinical and clinical data demonstrating that immune agonist antibody immunotherapies (IAAs) such as αOX40 induce strong antitumor immune responses, clinical translation has been significantly hampered by the propensity of some IAAs to induce dose‐limiting and sometimes life‐threatening immunotoxicities such as cytokine release syndrome and hepatotoxicity. For example, in a recent study αOX40 was shown to induce significant liver damage in mice by inducing the pyroptosis of liver natural killer T cells (NKT) cells. Surprisingly; however, given these previous reports, αOX40 treatment in our hands did not induce NKT cell pyroptosis or liver damage. We investigated numerous potential confounding factors including age, sex, tumor burden, dosing strategy, and the gut microbiota, which could have explained this discrepancy with the previous study. In none of these experiments did we find that αOX40 induced any more than very mild inflammation in the liver. Our study therefore suggests that, preclinically, αOX40 is a safe and effective immunotherapy and further studies into the clinical benefit of αOX40 are warranted.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2573-9832
Relation: https://doaj.org/toc/2573-9832
DOI: 10.1096/fba.2021-00039
Access URL: https://doaj.org/article/509e5b2e3ad24c65b61fa3b52ee3b1d6
Accession Number: edsdoj.509e5b2e3ad24c65b61fa3b52ee3b1d6
Database: Directory of Open Access Journals
More Details
ISSN:25739832
DOI:10.1096/fba.2021-00039
Published in:FASEB BioAdvances
Language:English